Globus Medical (GMED) Receives a Buy from Barclays
In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...
Jefferies raises Nevro stock rating, boosts price target to $5.85
Jefferies analyst Matthew Taylor revised the stock rating for Nevro Corp (NYSE:NVRO), elevating it from Underperform to Hold. Accompanying this upgrade, the price target also saw an increase to $5.85, ...
Globus Medical reaffirms FY25 stand-alone EPS $3.40-$3.50, consensus $3.47
On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...
MassDevice3d
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus Medical to buy California life sciences firm for $250M
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
Globus Medical to buy Nevro in $250M all-cash deal
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...
FY2024 EPS Estimates for Globus Medical Reduced by Analyst
Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...